DeepMed Research

H. Lee Moffitt Cancer Center and Research Institute, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma

Phase 2

Active, not recruiting

Conditions: Merkel Cell Carcinoma
Skin Cancer

Interventions: Drug: Nivolumab
Drug: Ipilimumab
Radiation: Stereotactic Body Radiation Therapy (SBRT)

First Posted Date: 2017-03-06

Last Posted Date: 2025-05-22

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 50

Registration Number: NCT03071406

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer

Phase 1

Completed

Conditions: Small Cell Lung Cancer
Extensive-stage Small Cell Lung Cancer

Interventions: Radiation: Thoracic Radiation Therapy
Drug: Ipilimumab
Drug: Nivolumab

First Posted Date: 2017-02-06

Last Posted Date: 2024-12-20

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 21

Registration Number: NCT03043599

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas

Phase 2

Terminated

Conditions: Pancreatic Cancer
Islet Cell Carcinoma
Gastro-enteropancreatic Neuroendocrine Tumor
Neuroendocrine Carcinomas of Pancreas

Interventions: Drug: FOLFIRINOX
Drug: Granulocyte colony-stimulating factor (G-CSF)

First Posted Date: 2017-02-03

Last Posted Date: 2020-11-27

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 2

Registration Number: NCT03042780

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Refining and Testing the Electronic Social Network Assessment Program (eSNAP)

Completed

Conditions: Brain Cancer

Interventions: Behavioral: eSNAP
Behavioral: Questionnaires

First Posted Date: 2017-01-20

Last Posted Date: 2020-12-02

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 62

Registration Number: NCT03026699

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT

Phase 1

Completed

Conditions: Non-Hodgkin's Lymphoma
Acute Leukemia in Remission
Hodgkin Lymphoma
Chronic Myeloid Leukemia
Chronic Myelomonocytic Leukemia
Multiple Myeloma
Primary Myelofibrosis
Myelodysplastic Syndromes

Interventions: Drug: Fludarabine
Drug: Busulfan
Drug: Cyclophosphamide
Radiation: Total body irradiation (TBI)
Procedure: Peripheral Blood Hematopoietic Cell Transplantation (HCT)
Drug: Sirolimus (SIR)
Drug: Mycophenolate mofetil (MMF)
Drug: Granulocyte-colony stimulating factor (G-CSF)

First Posted Date: 2017-01-11

Last Posted Date: 2021-09-16

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 32

Registration Number: NCT03018223

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma

Phase 1

Withdrawn

Conditions: Liver Cancer
HepatoCellular Carcinoma
Unresectable HepatoCellular Carcinoma

Interventions: Radiation: Stereotactic Body Radiation Therapy (SBRT)
Drug: Sorafenib
Drug: Bavituximab

First Posted Date: 2016-12-12

Last Posted Date: 2020-06-05

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Registration Number: NCT02989870

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Assess Gamma H2AX Positivity in Circulating Prostate Cancer Cells Before and After Radium 223

Completed

Conditions: Prostate Cancer
Prostate Adenocarcinoma

Interventions: Other: Blood Collection During Standard of Care Treatment

First Posted Date: 2016-12-05

Last Posted Date: 2021-06-11

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 10

Registration Number: NCT02981797

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Determinants of Age-Related Treatment Effectiveness in Ovarian Cancer

Completed

Conditions: Ovarian Cancer
Ovarian Diseases
Fallopian Tube Cancer
Fallopian Tube Diseases
Peritoneal Diseases
Peritoneal Cancer

Interventions: Procedure: Baseline Biopsy
Procedure: Tissue Collection
Procedure: Blood Draws

First Posted Date: 2016-11-25

Last Posted Date: 2023-01-26

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 20

Registration Number: NCT02973750

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer

Phase 2

Active, not recruiting

Conditions: Kidney Cancer

Interventions: Drug: Pembrolizumab
Drug: Interleukin-2

First Posted Date: 2016-11-15

Last Posted Date: 2025-04-03

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 27

Registration Number: NCT02964078

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Therasphere for Unresectable Primary or Secondary Liver Neoplasia

Conditions: Liver Cancer
Liver Neoplasms
HepatoCellular Carcinoma

First Posted Date: 2016-11-09

Last Posted Date: 2022-09-28

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Registration Number: NCT02960620

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy